Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Amortizatization of Intangibles: 2019-2025

Historic Amortizatization of Intangibles for Abeona Therapeutics (ABEO) over the last 6 years, with Sep 2025 value amounting to $280,000.

  • Abeona Therapeutics' Amortizatization of Intangibles rose 19.15% to $280,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 14.06%. This contributed to the annual value of $903,000 for FY2024, which is 0.77% down from last year.
  • Per Abeona Therapeutics' latest filing, its Amortizatization of Intangibles stood at $280,000 for Q3 2025, which was down 70.83% from $960,000 recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Amortizatization of Intangibles high stood at $960,000 for Q2 2025, and its period low was -$455,000 during Q1 2025.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $230,000 (2023), whereas its average is $236,182.
  • The largest annual percentage gain for Abeona Therapeutics' Amortizatization of Intangibles in the last 5 years was 384.85% (2025), contrasted with its biggest fall of 295.28% (2025).
  • Over the past 5 years, Abeona Therapeutics' Amortizatization of Intangibles (Quarterly) stood at $389,000 in 2021, then dropped by 28.02% to $280,000 in 2022, then dropped by 17.86% to $230,000 in 2023, then climbed by 3.04% to $237,000 in 2024, then increased by 19.15% to $280,000 in 2025.
  • Its last three reported values are $280,000 in Q3 2025, $960,000 for Q2 2025, and -$455,000 during Q1 2025.